Skip to Content

'
Luhua (Michael) Wang, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Director, Myeloma Tissue Bank, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 429
Houston, TX 77030
Room Number: Faculty Center, FC6.2038
Phone: (713) 792-2860
Fax: (713) 563-5067
Email: miwang@mdanderson.org

Education & Training

Degree-Granting Education

1988 Beijing Medical University, Beijing, China, MS, Physiology
1985 Shandong Medical University, Jinan, China, MD, Medicine

Postgraduate Training

7/1999-6/2002 Medical Oncology/Hematology Fellow, University of Texas M.D. Anderson Cancer Center, Houston, TX, Robert Wolff, MD
7/1997-6/1998 Chief Medical Resident, Yale-Norwalk Hospital, Norwalk, CT, Joseph Cleary, MD and Eric Mazur, MD
7/1995-6/1997 Residency, Yale-Norwalk Hospital, Norwalk, CT, Joseph Cleary, MD and Eric Mazur, MD
6/1994-6/1995 Internship, Dept. of Internal Medicine, The University of Michigan Hospitals, Ann Arbor, MI, T. Yamada, MD
2/1991-6/1994 Visiting Associate, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, Vincent Manganiello, M.D.
10/1988-1/1991 Visiting Fellow (Recipient of Fogarty International Fellowship Award), National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, Robert Jensen, M.D.

Board Certifications

1/2004 American Board of Internal Medicine, Medical Oncology
1/1998 American Board of Internal Medicine, Internal Medicine

Experience/Service

Academic Appointments

Clinical Specialist, University of Texas M. D. Anderson Cancer Center, Houston, TX, 12/2001-6/2002
Instructor, Dept. of Internal Medicine, University of Texas Medical School, Houston, TX, 7/1998-6/1999
Chief Medical Resident, Yale-Norwalk Hospital, Norwalk, CT, 7/1997-6/1998
Visiting Associate, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, 2/1991-6/1994

Other Appointments/Responsibilities

Medical Liaison in Myeloma, M.D. Anderson Cancer Center - Orlando, Orlando, FL, 11/2002-present

Institutional Committee Activities

Member, Clinical Research Committee 3, M.D. Anderson Cancer Center, 2009-2010
Member, China Steering Committee, Extramural Programs, M.D. Anderson Cancer Center, 9/2005-present
Member, Clinical Research Committee M.D. Anderson Cancer Center, 7/2005-7/2006
Member, Clinical and Translational Research Steering Committee M.D. Anderson Cancer Center, 2/2005-6/2006
Member, NCI Sponsored Clinical Trial Faculty M.D. Anderson Cancer Center, 11/2002-present
Member, Internal Advisory Committee to Complementary Integrative Medicine M.D. Anderson Cancer Center, 1/2002-1/2004

Honors and Awards

2007 America's Top Oncologist
2006-2007 Who's Who Among Executive and Professionals in Nursing and Healthcare, Cambridge Who's Who
1997-1998 Recognition Award for Outstanding Service as Chief Resident in Medicine, Norwalk Hospital, Norwalk, CT
1988-1990 Fogarty International Fellowship Award, National Institutes of Health, Bethesda, MD

Selected Publications

Peer-Reviewed Original Research Articles
1. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, Yi Q. Cyclin D1 as a universally-expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 23(7):1320-1328, 07/19/2009, 7/2009. e-Pub 2/2009. PMID: 19225534.
2. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 10(4)(4):295-307, 2006. PMID: 17045207.
3. Wang M, Giralt S, Delasalle K, Alexanian R. Bortezomib in combination with Thalidomide-Dexamethasone for previously untreated myeloma. Haematology 12(3):235-239, 2007.
4. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera J, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 109(12):5455-62, 6/2007. e-Pub 2/22/2007. PMID: 17317853.
5. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12(3):252-65, 9/2007. PMID: 17785206.
6. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Knight RD. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133-42, 11/2007. PMID: 18032763.
7. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 14(7):2154-2160, 4/2008. PMID: 18381957.
8. Zhou Y, Wang H, Fang W, Romaguera J, Zhang Y, Delasalle K, Kwak L, Yi Q, Du X, Wang M. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113(4):791-798, 8/2008. PMID: 18615506.
9. Wang M, Fayad L, Hagemeister F, McLaughlin P, Rodriguez A, Cabanillas F, Younes A, Neelapu S, Goy A, Zhou Y, Wang J, Beasley V, Kwak L, Kantarjian H, Romaguera J. Phase II trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed/refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-2741, 11/15/2008, 11/2008. PMID: 18973182.
10. Wang M, Simopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112(12):4445-4451, 12/2008. PMID: 18799726.
11. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status and survival in a large population-based cohort of elderly patients with non-Hodgkin's Lymphoma. Cancer 113(11):3231-3241, 12/2008. PMID: 18937267.
12. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelonini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a Phase II randomized trial. Biology of Blood and Marrow Transplantation, 12/2008. PMID: 19041063.
13. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol, 9/2009. e-Pub 6/2009. PMID: 19565649.

Invited Articles
1. Wang ML, Younes A. Testicular lymphoma: a mysterious link between the testis and the brain. Clin Lymphoma 3:173-4, 2002. PMID: 12521395.

Abstracts
1. Wang M, Zhang L, Fayad L, Hagemeister F, Neelapu S, Samaniego F, Pro B, Miller S, Knight R, Zeldis J, Yi Q, Romaguera J. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a Phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 112(11) (#3058), 11/2008.
2. Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, Romaguera J. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. Proc ASCO 25(18S):8030, 2007.
3. Wang M, Shi Y, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Romaguera J, Kwak L, Yi Q. A SCID-hu in vivo mouse model of human primary mantle cell lymphoma. Blood 110(11):691a, abstr 2337, 2007.
4. Wang M, Delasalle K, Thomas S, Qazilbash M, Giralt S, Weber D, Alexanian R. Early transplant is useful for older patients with multiple myeloma. Haematologica 92(6):189, (abstr PO-819), 2007.
5. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnyckyj M, Weber D. Effect of Lenalidomide/Dexamethasone in multiple myeloma despite Thal resistance. Haematologica 92(6):172, (abstr PO-662), 2007.
6. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide (Len) in combination with Rituximab demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory mantle cell lymphoma (MCL). Blood 110(11):755a, abstr 2562, 2007.
7. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with Bortezomib-Lenalidomide-Dexamethasone (BLD). Blood 110(11):1057a, abstr 3611, 2007.
8. Wang M, Zhou Y, Wang H, Yi Q, Zhang Y, Alexanian R, Kwak L, Du X. Trend and geographic variations in the incidence of Waldenstrom's Macroglobulinemia in the United States over 17 years from 1988 to 2004. Blood 110(11):5174, 2007.
9. Wang M, Zhang L, Han X, Yang J, Qian J, Wang S, Hong S, Zhang X, Zhou Y, Romaguera J, Yi Q. Atiprimod inhibits growth of mantle cell lymphoma in vitro and in vivo and induced apoptosis via activation of the mitochondrial pathway. Blood 108(11):712a, (abstr 2514), 2006.
10. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Yu Z, Zeldis J, Olesnyckyj, Weber DM. Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received thalidomide in relapsed or refractory multiple myeloma (MM). J Clin Oncol 24(18S):7522, 2006.
11. Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 108(11):123a, (abstr 403), 2006.
12. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnyckyj, Weber D. Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma. Blood, 2006.
13. Wang M, Oki Y, Pro B, Romaguera J, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Podoloff D, Samuels B, Loyer E, Zhou Y, Younes A. Phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 108(11):767a, (abstr 2714), 2006.
14. Zhang L, Shi Y, Han X, Yang J, Qian J, Kwak L, Romaguera J, Yi Q, Wang M.. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 110(11)(1):4514, 2007. e-Pub 9/27/2007. PMID: 17898787.
15. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-816, http://www.ncbi.nlm.nih.gov/sites/entrez, 7/2009. e-Pub 7/2009. PMID: 19539212.
16. M. Wang, A. Gutierrez, R. Niesvizky, B. Bensinger, M. Vallone, A.A. Gutierrez, M. Kauffman. PX-171-006: Phase IB multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low dose dexamethasone (LODEX) in relapsed and refractory multiple myeloma (MM) -- Preliminary results. Haematologica Journal (#1070). In Press.

Last updated: 9/18/2009